T1	p 328 370	95 patients with atherosclerotic disease .
T2	p 1985 2046	patients who are on a diet enriched with polyunsaturated fats
T3	i 78 102	lipid-lowering treatment
T4	i 108 125	diet , clofibrate
T5	i 130 142	niceritrol .
T6	i 300 324	lipid-lowering treatment
T7	i 419 423	diet
T8	i 478 527	clofibrate or niceritrol , a nicotinic acid ester
T9	i 647 679	diet , clofibrate and niceritrol
T10	i 1239 1243	diet
T11	i 1268 1278	clofibrate
T12	i 1285 1295	niceritrol
T13	i 1360 1380	Clofibrate treatment
T14	i 2283 2303	clofibrate treatment
T15	i 2374 2380	diet .
T16	o 21 70	fatty acid composition of the plasma lipid esters
T17	o 174 183	linoleate
T18	o 226 275	fatty acid composition of the plasma lipid esters
T19	o 706 717	serum lipid
T20	o 735 784	fatty acid composition in the plasma lipid esters
T21	o 917 969	content of saturated and monounsaturated fatty acids
T22	o 988 1015	polyunsaturated fatty acids
T23	o 1045 1114	ratio between pulyunsaturated and saturated fatty acids ( P/S ratio )
T24	o 1197 1212	phospholipids .
T25	o 1335 1359	fatty acid composition .
T26	o 1418 1445	monounsaturated fatty acids
T27	o 1459 1465	oleate
T28	o 1507 1538	triglycerides and phospholipids
T29	o 1586 1621	content of linoleic ( 18 : 2 ) acid
T30	o 1770 1779	P/S ratio
T31	o 1852 1873	saturated fatty acids
T32	o 2080 2153	polyunsaturated to monounsaturated fatty acids in the plasma lipid esters
T33	o 2192 2249	ratio between polyunsaturated and saturated fatty acids .
T34	o 2260 2272	acid changes